^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3461 - Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
Published date:
03/15/2023
Excerpt:
The current objective response rate (ORR) among the 14 patients who have at least one post assessment scan is 3/14 (21%; 1 G12V, 1 G12A, 1 G13A) with 11/14 showing a reduction in tumor size as best response....We have shown that avutometinib and everolimus induce synergistic anti-tumor effects preclinically, and preliminary data suggest clinically meaningful ORR and PFS in patients with KRAS mt NSCLC including non-G12C variants.
Secondary therapy:
everolimus
Source:
Title:
Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.
Published date:
05/26/2022
Excerpt:
In the KRAS mt NSCLC expansion cohort, 10 patients are evaluable for efficacy and 2 confirmed responses were reported (KRAS mutations G12V and G13A) with an objective response rate (ORR) 20% to date….The median progression free survival (PFS) in the KRAS mt NSCLC cohort is 6.35 months (95% CI 3.52 – not reached)....The combination of VS-6766 with everolimus has shown activity in patients with a variety of KRAS mutation variants including responses in KRAS mt NSCLC.
Secondary therapy:
everolimus
DOI:
10.1200/JCO.2022.40.16_suppl.9018
Source:
Title:
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I
Excerpt:
Subsequent Combined Analysis (VS-6766 Monotherapy and Defactinib Combination) Demonstrates 57% (4/7 Patients) Overall Response Rate in KRASG12V Non-Small Cell Lung Cancer.
Source:
Title:
P52.05 - Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
Published date:
08/18/2021
Excerpt:
In a KRAS G12V mt/TP53 null NSCLC model, which has previously been shown to be CRAF dependent, VS-6766 monotherapy induced statistically significant tumor regression...
